Nintedanib Worsens Outcomes Along With Chemo in Advanced Ovarian Cancer

A phase II trial showed that the addition of nintedanib to neoadjuvant chemotherapy did not benefit patients with advanced epithelial ovarian cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news